Accessibility StatementSkip Navigation SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the "Class Period"), have until November 10, 2025 to seek appointment as lead plaintiff of the Lantheus class action lawsuit. Captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv- 07491 (S.D.N.Y.), the Lantheus class action lawsuit charges Lanth ...

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly providing misleading information to investors regarding the competitive position of its product Pylarify during the class period from February 26, 2025, to August 5, 2025 [1][2]. Group 1 - The lawsuit claims that Lantheus made overwhelmingly positive statements while concealing material adverse facts about Pylarify's competitive dynamics [2]. - It is alleged that the company was not adequately equipped to assess pricing and competition for Pylarify, which led to a risk of price erosion and affected revenue and growth potential [2]. - The complaint states that these misleading statements resulted in shareholders purchasing Lantheus securities at artificially inflated prices [2]. Group 2 - Investors who acquired shares of Lantheus are encouraged to contact the law firm before the lead plaintiff motion deadline on November 10, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation process [3].

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Robbins LLPÂ informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products. The Company's key Radiopharmaceutical Oncology product is Pylarify, a PET i ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) between February 26, 2025, to August 5, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Stanley Margolis v. Lantheus Holdings, Inc., et al. (Case No. 1:25-cv-07491) has been commenced in the United States District Court ...

BOSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against Lantheus Holdings Inc. (Nasdaq: LNTH) and certain of its executives. Investors who have lost money in their Lantheus Holdings Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/lnth. What is this all about? The complaint alleges that Lantheus and its executives misled investors about th ...

Lantheus Holdings LNTH shares fell Wednesday after U.S. health agencies proposed changes to Medicare payment rules for hospital outpatient services and surgical centers starting in 2026.The proposal outlines changes in how payment rates are calculated for services under the Hospital Outpatient Prospective Payment System (OPPS) and the ASC payment system.The CMS has proposed maintaining the $140 packaging threshold for drugs, biologicals, and therapeutic radiopharmaceuticals for calendar year (CY) 2026 under ...

Core Viewpoint - Lantheus Holdings (NASDAQ: LNTH) presents a strong investment case driven by its flagship product Pylarify, which is a leading imaging agent in a growing market, alongside its established product Definity for echocardiograms [1] Product Analysis - Pylarify is recognized as a best-in-class imaging agent, indicating its competitive advantage in the market [1] - Definity has a long-standing history of market leadership, suggesting stability and reliability in its performance [1] Market Context - The market for imaging agents is expected to grow, which could benefit Lantheus Holdings significantly due to its strong product offerings [1]

Core Viewpoint - Investors should focus on pharmaceutical stocks that are currently trading at extremely oversold levels, as indicated by the Relative Strength Index (RSI), which can signal potential rebounds [1][13]. Group 1: Sarepta Therapeutics - Sarepta Therapeutics has an RSI of 22, indicating extreme oversold conditions, and has seen its stock price drop over 40% following an earnings miss [2][3]. - The 12-month stock price forecast for Sarepta is $131.22, suggesting a potential upside of 262.48% from the current price of $36.20 [2]. - Analysts, including those from Wells Fargo, maintain a Buy rating and are optimistic about Sarepta's long-term pipeline, particularly its FDA-approved gene therapy for Duchenne muscular dystrophy [3][4]. Group 2: Krystal Biotech - Krystal Biotech's RSI has risen to 33, indicating a recovery from oversold levels, with a recent stock price of $134.53 [5][6]. - The 12-month stock price forecast for Krystal is $218.63, representing a potential upside of 62.51% [5]. - Analysts remain bullish on Krystal, with Guggenheim reiterating a Buy rating and a price target of $189, indicating nearly 40% upside potential [7][8]. Group 3: Lantheus Holdings - Lantheus Holdings has an RSI of 28, showing signs of being oversold after a 25% drop following an earnings miss [9][10]. - The 12-month stock price forecast for Lantheus is $132.67, suggesting a potential upside of 68.04% from the current price of $78.95 [9]. - Truist Financial has reiterated a Buy rating with a price target of $117, indicating more than 45% upside potential, supported by the company's strong product portfolio [11][10].

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has filed a provisional patent application for "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy," which is a significant step in advancing its diagnostic and therapeutic programs for prostate cancer [1][7]. Company Overview - Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company founded in 2012, focused on improving outcomes for cancer patients treated with radiation therapy [8]. - The company aims to develop therapies that maximize the effectiveness of radiation therapy while minimizing side effects, thereby improving cancer cure rates and patient quality of life [8]. Research and Development - The provisional patent application is part of the company's efforts to create highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, utilizing PSMA ligands for accurate imaging and targeted therapy delivery [1][7]. - The collaboration with Dr. Alan Kozikowski, a pioneer in PSMA targeting, has been instrumental in the development of these therapeutic agents [2][5]. Market Potential - The global PSMA PET imaging market was valued at $1.5 billion in 2022 and is projected to reach $2.0 billion by 2030, indicating significant growth potential in this area [7]. - The targeted radiopharmaceutical treatment Pluvitco® for PSMA-positive metastatic prostate cancer is expected to have a market size of $2 billion [7]. Diagnostic Initiatives - Shuttle Diagnostics, a subsidiary of Shuttle Pharmaceuticals, is focused on developing pretreatment diagnostic blood tests for prostate cancer patients, including the PSMA-B ligand and the PC-Rad test [4]. - Currently, there are no available tests on the market that can predict treatment success for prostate cancer specifically [4]. Scientific Collaboration - The company has collaborated with Dr. Kozikowski and other researchers to discover novel PSMA ligands aimed at enhancing the targeting of prostate cancer cells [5][6]. - The research into antibody-drug conjugates (ADCs) and the advantages of smaller PSMA targeting ligands for drug delivery is a promising area of exploration [3].